Atopic eczema, also known as atopic dermatitis, is one of the most common inflammatory skin conditions worldwide. If you have eczema, you may experience persistent itching, dry skin, inflammation, and painful flare-ups that can affect your daily routine, sleep, confidence, and overall quality of life. Although symptoms vary from person to person, the condition can have a significant impact on both your physical and emotional wellbeing.
For many years, treatment for moderate-to-severe eczema relied on topical therapies, phototherapy and broader systemic immunomodulatory treatments. Although these approaches can be effective, some patients continue to have inadequately controlled disease or require alternatives because of treatment limitations, adverse effects or monitoring requirements.
The LIBERTY AD clinical trial programme marked a major breakthrough in eczema care by introducing a new approach to treatment. These large Phase III studies showed that dupilumab could significantly improve eczema symptoms, reduce flare-ups, and enhance quality of life for many people with moderate-to-severe atopic dermatitis. As a result, eligible patients now have access to a targeted biologic treatment that has significantly changed the management of moderate-to-severe atopic dermatitis.
Understanding Atopic Eczema
Atopic eczema is a long-term inflammatory skin condition that develops because of a combination of genetic, immune, and environmental factors. If you have eczema, you may notice dry, sensitive skin along with redness, swelling, and intense itching that can become difficult to manage during flare-ups. The severity of your symptoms can vary over time, with periods of improvement followed by sudden worsening.
Although atopic eczema often begins in childhood, it can continue into adulthood or even develop later in life. You may experience mild, occasional symptoms, or you may have more widespread eczema that requires ongoing specialist care and treatment. Because everyone’s experience is different, finding the right treatment plan is an important part of managing the condition.
Over the years, researchers have gained a much better understanding of the biological processes that drive atopic eczema. This improved knowledge has helped develop more targeted treatments that focus on the underlying causes of inflammation rather than simply relieving your symptoms, offering new hope for better long-term control.
The Need for New Eczema Treatments
Before biologic therapies became available, most eczema treatments focused on controlling symptoms rather than targeting the underlying cause of the condition. If you had moderate-to-severe eczema, you may have relied on topical creams, phototherapy, or immune-suppressing medicines to manage flare-ups and reduce inflammation. While these treatments helped many people, they did not always provide consistent or long-lasting relief.
For some people, eczema continued to flare up despite following their prescribed treatment plan carefully. You may also have found that certain medicines were not suitable for long-term use because of their potential side effects or limited effectiveness. This highlighted the need for additional effective treatment options with appropriate long-term safety monitoring that could provide better long-term control.
Researchers recognised that targeting the specific immune pathways involved in type 2 inflammation could offer a more effective approach. By focusing on the biological processes driving inflammation, newer therapies aim to help you achieve better symptom control, reduce flare-ups, and improve your overall quality of life.
Long-Term Evidence Note
Long-term extension research has provided information beyond the original 16-week and one-year controlled trials.
The LIBERTY AD open-label extension enrolled 2,677 adults who had previously taken part in dupilumab clinical studies. The final analysis assessed safety and effectiveness for up to five years of treatment.
Among patients with available assessments at week 260, 67.5% achieved clear or almost clear skin on the Investigator’s Global Assessment and 88.9% achieved EASI-75.
These findings support sustained long-term disease control for many patients who continue treatment. However, the results should be interpreted differently from the original randomised placebo-controlled trials. The extension study was open-label, did not have a placebo control group, treatment regimens changed during the study, and patient numbers were much smaller at later time points.
For you as a patient, the practical message is that dupilumab can provide sustained benefit during long-term treatment for many people, but your response should still be reviewed individually over time.
UK Clinical Practice Note
In the UK, it is important to distinguish between the medicine’s marketing authorisation and specific NICE recommendations.
Current UK product information indicates dupilumab for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and over who are candidates for systemic therapy. It is also indicated for severe atopic dermatitis in children aged 6 months to 11 years who are candidates for systemic therapy.
For adults, NICE recommends dupilumab as an option for moderate-to-severe atopic dermatitis when the disease has not responded to at least one other systemic treatment, such as ciclosporin, methotrexate, azathioprine or mycophenolate mofetil, or when these treatments are contraindicated or not tolerated.
NICE recommends assessing treatment response at 16 weeks. Under TA534, an adequate adult response requires both at least a 50% reduction in EASI score and at least a four-point improvement in the Dermatology Life Quality Index.
For patients, this means that dupilumab is an established targeted treatment, but it is not automatically the first treatment offered to everyone with eczema. Treatment decisions depend on age, severity, previous treatment, response to therapy and the relevant commissioning pathway.
Clinical Safety Note
Dupilumab was generally well tolerated in the pivotal trial programme, but treatment is not free from possible adverse effects.
Common recognised adverse reactions include injection-site reactions, conjunctivitis, allergic conjunctivitis, oral herpes, arthralgia and eosinophilia. Eye symptoms are particularly important because conjunctivitis and other ocular surface problems have been reported more frequently in people receiving dupilumab for atopic dermatitis.
Tell your healthcare professional promptly if you develop new or worsening eye symptoms during treatment. Sudden changes in vision or significant eye pain that does not settle require urgent medical review.Depending on the nature and severity of your symptoms, additional assessment or ophthalmic advice may be appropriate.
The safety discussion should remain balanced: dupilumab does not broadly suppress the immune system in the same way as traditional systemic immunosuppressants, but treatment still requires appropriate specialist selection, counselling and follow-up.
What Is Dupilumab?
Dupilumab is a biologic medicine that has been developed to target the underlying immune processes involved in atopic eczema. If you have moderate-to-severe eczema, Dupilumab is a monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, or IL-4Rα. This inhibits signalling by IL-4 and IL-13, two important cytokines involved in type 2 inflammation. which play a major role in driving inflammation. By targeting these pathways, dupilumab helps target key inflammatory pathways involved in atopic dermatitis rather than simply treating its symptoms.
When the activity of IL-4 and IL-13 is reduced, reducing IL-4 and IL-13 signalling can decrease important components of type 2 inflammation associated with atopic dermatitis This can help you experience less itching, reduced skin inflammation, fewer flare-ups, and healthier skin over time. Many people also notice improvements in their sleep and overall quality of life as their symptoms become better controlled.
Unlike conventional systemic immunosuppressive treatments that have broader immune effects, dupilumab targets specific signalling pathways involved in type 2 inflammation.This represented a major advance in eczema care and has changed the way doctors treat people with moderate-to-severe atopic dermatitis, offering you a more effective long-term treatment option.
The Purpose of the LIBERTY AD Programme
The LIBERTY AD clinical trial programme was designed to find out whether dupilumab could provide a safe and effective treatment for people with moderate-to-severe atopic eczema. If you have eczema that has not responded well to conventional treatments, these studies aimed to determine whether dupilumab could offer better long-term control of your symptoms. The programme focused on generating strong clinical evidence to support its use in everyday practice.
Researchers wanted to understand whether dupilumab could reduce the severity of eczema, relieve persistent itching, and improve your overall quality of life. They also assessed whether the treatment could help reduce the frequency of flare-ups and allow you to manage your condition more effectively over time. These outcomes were important because eczema can affect much more than just your skin.
To answer these questions, the LIBERTY AD programme included several large international clinical trials involving thousands of participants. By studying people from different backgrounds and healthcare settings, researchers were able to gather reliable evidence about how well dupilumab works and how it may benefit you in real-world clinical practice.
Evidence Note: What Did SOLO 1 and SOLO 2 Actually Show?
SOLO 1 and SOLO 2 were two similarly designed Phase III trials involving a total of 1,379 adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatment or for whom topical treatment was not medically advisable.
Among participants receiving dupilumab every two weeks, clear or almost clear skin was achieved by 38% in SOLO 1 and 36% in SOLO 2, compared with 10% and 8% of patients receiving placebo.
A 75% or greater improvement in the Eczema Area and Severity Index, known as EASI-75, was achieved by 51% and 44% of patients receiving every-two-week dupilumab, compared with 15% and 12% receiving placebo.
Clinically meaningful itch improvement was also more common with dupilumab. A reduction of at least four points on the Peak Pruritus Numerical Rating Scale was achieved by 41% and 36% of patients receiving the every-two-week regimen, compared with 12% and 10% receiving placebo.
For you as a patient, these results mean that dupilumab improved more than the visible appearance of eczema. The pivotal trials showed benefits across skin severity, itch and patient-reported outcomes, which helps explain why the treatment represented such a major change in moderate-to-severe eczema care.
Phase III Clinical Trial Design
The LIBERTY AD studies were large Phase III clinical trials that used a randomised, double-blind, and placebo-controlled design. This type of research is considered one of the highest standards in medical science because it helps ensure that the results are accurate, reliable, and free from unnecessary bias. If you are looking at the evidence behind dupilumab, this rigorous study design provides greater confidence in the findings.
During the trials, participants were randomly assigned to receive either dupilumab or placebo injections. Neither you as a participant nor the researchers knew which treatment was being given during the blinded phase, helping to ensure that expectations did not influence the results. This approach allowed scientists to make a fair and objective comparison between the two groups.
By carefully monitoring changes in eczema severity, itching, skin appearance, and overall wellbeing, researchers were able to measure the true impact of dupilumab. The results provided strong scientific evidence that helped doctors understand how the treatment could benefit you if you have moderate-to-severe atopic eczema.
Better Quality of Life Outcomes
Atopic eczema can affect much more than just your skin. If you are living with the condition, you may experience embarrassment about visible flare-ups, anxiety, poor sleep, and difficulty carrying out everyday activities. These challenges can have a significant impact on your confidence, relationships, work, and overall wellbeing.
The LIBERTY AD clinical trials showed that dupilumab improved patient-reported quality of life alongside reducing eczema symptoms. As your skin becomes clearer and your itching is better controlled, you may find it easier to sleep through the night, stay focused during the day, and take part in activities that you previously avoided. These improvements can make a noticeable difference to your daily life.
The study findings highlighted the importance of treating the whole person rather than focusing only on visible skin changes. By addressing both the physical and emotional effects of eczema, dupilumab has helped provide you with a more comprehensive approach to long-term eczema management.
Measuring Eczema Improvement
Researchers in the LIBERTY AD trials used standardised assessment tools to measure how well dupilumab improved eczema. These tools assessed skin inflammation, eczema severity, itching, and the impact of symptoms on daily life. Using consistent methods helped researchers compare treatment results accurately.
- Eczema Severity Scores: Researchers measured changes in the extent and severity of eczema throughout treatment.
- Itch Assessment: Changes in itching were monitored to understand how treatment affected one of the most troublesome eczema symptoms.
- Flare-Up Control: Researchers assessed whether dupilumab reduced the frequency and intensity of eczema flare-ups over time.
- Quality of Life Measures: Standardised tools also examined how eczema improvement affected sleep, comfort, and everyday activities.
Overall, standardised assessment tools helped provide reliable evidence of how effectively dupilumab controlled moderate-to-severe eczema. By measuring both visible skin changes and the impact of symptoms on daily life, researchers gained a broader picture of treatment response. These findings support more informed long-term treatment decisions for suitable patients.
Reduction in Eczema Severity
The LIBERTY AD studies showed that many people receiving dupilumab experienced significant improvements in their eczema symptoms. If you have moderate-to-severe atopic eczema, these findings suggest that a targeted biologic treatment can help reduce inflammation, improve your skin, and make flare-ups easier to manage. Many participants noticed meaningful improvements after starting treatment.
When compared with the placebo group, a much higher number of people treated with dupilumab achieved clinically significant reductions in eczema severity. This meant that you were more likely to experience clearer skin and better control of your symptoms when receiving dupilumab than with placebo alone. The consistent results across multiple studies strengthened the evidence supporting the treatment.
These findings demonstrated that targeting specific immune pathways could produce major clinical benefits for people with eczema. By addressing the immune pathways contributing to inflammation rather than simply relieving symptoms, dupilumab has helped change the way doctors treat moderate-to-severe atopic eczema and has provided you with a more effective long-term treatment option.
Improvement in Itching Symptoms
Itching is one of the most challenging symptoms of atopic eczema and can have a major impact on your everyday life. If you experience persistent itching, you may find it difficult to sleep, concentrate at work or school, or enjoy daily activities. Constant scratching can also damage your skin, increasing the risk of further irritation and flare-ups.
The LIBERTY AD programme showed that dupilumab could significantly reduce itch severity for many people with moderate-to-severe eczema. As your itching improves, you may notice that you scratch less often, allowing your skin to heal more effectively and making flare-ups easier to manage. Many participants experienced noticeable relief during the clinical trials.
Reducing itching can make a meaningful difference to your overall quality of life. With fewer interruptions to your sleep and greater comfort throughout the day, you may find it easier to manage your condition and regain confidence in your daily routine.
Safety Profile of Dupilumab
Safety was a key focus throughout the LIBERTY AD clinical trial programme, with researchers carefully monitoring participants during every stage of treatment. If you are considering dupilumab, it is reassuring to know that the studies found the medicine was generally well tolerated by most people with moderate-to-severe atopic eczema. This helped build confidence in its use as a long-term treatment option.
Like all medicines, dupilumab can cause side effects, although many people experience only mild or manageable reactions. You may develop injection site reactions or certain eye-related symptoms, such as redness or irritation, but these can often be managed with appropriate medical advice and follow-up care. Your dermatologist will monitor your response to treatment and help address any concerns that arise.
Long-term safety monitoring has continued since dupilumab was approved for clinical use. This ongoing research helps doctors better understand how the treatment performs over time and ensures that you continue to receive care based on the latest evidence and safety information.
The Importance of Biologic Therapies
Dupilumab became the first approved biologic treatment for atopic dermatitis and helped establish targeted biologic therapy as an important option for suitable patients with moderate-to-severe disease. If you have struggled to control your eczema with traditional treatments, this breakthrough offered a new option that targets the underlying causes of the condition rather than simply relieving its symptoms. It marked an important step forward in the way eczema is treated.
The success of dupilumab showed that eczema is much more than a condition caused by dry or sensitive skin. Researchers discovered that your immune system plays a central role in driving inflammation, itching, and recurring flare-ups. This improved understanding has changed the way doctors approach eczema treatment and long-term disease management.
These findings have encouraged the development of additional targeted biologic therapies for atopic eczema. As research continues to advance, you may benefit from an increasing range of treatments that are designed to match your individual needs and provide better long-term control of your symptoms.
Changing the Approach to Eczema Management
Before biologic medicines became available, Eczema treatment has traditionally used a stepwise approach involving skin care, topical anti-inflammatory treatment, phototherapy and systemic therapies according to disease severity and treatment response. If you had moderate-to-severe eczema, you may have needed stronger treatments over time as your symptoms became more difficult to manage. While these approaches could provide relief, they did not directly target the underlying cause of the condition.
Dupilumab introduced a new treatment strategy by targeting the immune pathways that drive eczema rather than simply treating inflammation on the surface of your skin. By addressing the important type 2 inflammatory pathways involved in the disease , the treatment aims to reduce flare-ups, improve your skin, and provide more consistent long-term symptom control. This represented a major shift in the way doctors manage atopic eczema.
As a result, expectations for people with severe eczema have changed significantly. You now have access to treatment options that are designed to provide longer-lasting control, improve your quality of life, and help you manage your condition more effectively over time.
Impact on Children With Eczema
Researchers have also studied how dupilumab can help children with moderate-to-severe atopic eczema. If your child has persistent eczema that is difficult to control, these studies have provided valuable information about the treatment’s effectiveness and safety in younger patients. This research has helped expand treatment options for children who need more than conventional therapies.
Severe childhood eczema can affect many aspects of your child’s life, including sleep, school performance, confidence, and emotional wellbeing. Constant itching and frequent flare-ups may also place additional stress on you and your family, making everyday routines more challenging. Managing the condition effectively is therefore important for both physical and emotional health.
The availability of newer treatments such as dupilumab has provided additional support for families managing difficult eczema. By improving symptom control and reducing flare-ups, you may find it easier to help your child enjoy a better quality of life and take part more comfortably in everyday activities.
Long-Term Benefits of Dupilumab
Long-term extension studies have helped researchers understand how dupilumab performs when used over extended periods. If you are considering this treatment, these studies provide valuable information about whether the benefits can be maintained with continued therapy. They also help doctors understand how your skin may respond over months and years of treatment.
Many people who continued using dupilumab maintained improvements in their eczema severity, itching, and overall quality of life. As you remain on treatment under the guidance of your dermatologist, you may continue to experience better symptom control and fewer flare-ups. These long-term results have been encouraging for both patients and healthcare professionals.
The growing body of long-term evidence has strengthened confidence in dupilumab as an effective management option for moderate-to-severe atopic eczema. By demonstrating lasting benefits and a favourable safety profile, these studies have helped reassure you and your doctor that biologic therapy can play an important role in long-term eczema care.
Influence on Future Eczema Research
The success of the LIBERTY AD programme has encouraged researchers to continue developing new targeted treatments for atopic eczema. If you have moderate-to-severe eczema, this progress means that more treatment options are becoming available to address the underlying causes of the condition rather than simply managing its symptoms. Dupilumab has played an important role in shaping this new direction in eczema research.
Scientists are now investigating a range of biologic medicines and small-molecule therapies for eczema and other inflammatory skin conditions. These treatments aim to target different immune pathways, giving you more personalised options depending on your symptoms, disease severity, and treatment response. Ongoing clinical trials continue to improve our understanding of which therapies work best for different patients.
Dupilumab helped open the door to a new generation of advanced eczema treatments. As research continues to evolve, you may benefit from even more effective therapies that offer better long-term symptom control, fewer flare-ups, and an improved quality of life.
Combining Treatments for Better Results
Although dupilumab can be highly effective for managing moderate-to-severe atopic eczema, it is often only one part of your overall treatment plan. If you are receiving biologic therapy, your dermatologist may also recommend daily moisturisers and other supportive treatments to help protect your skin and reduce the risk of flare-ups. Taking a combined approach can provide more comprehensive care.
Even when your symptoms improve with dupilumab, maintaining a regular skincare routine remains important. Using emollients consistently can help keep your skin hydrated, strengthen its natural barrier, and reduce dryness and irritation. Depending on your individual needs, you may also require additional treatments during occasional flare-ups.
By combining different treatment approaches, you can often achieve better long-term control of your eczema. Working closely with your dermatologist allows you to develop a personalised care plan that supports healthier skin, improves symptom management, and helps you maintain the best possible quality of life.
How Dupilumab Fits Into a Wider Eczema Management Plan
| Part of the Care Plan | Main Role | Why It May Still Matter During Dupilumab Treatment |
| Dupilumab | Targets IL-4 and IL-13 signalling involved in type 2 inflammation | Provides targeted systemic treatment for eligible patients with more severe disease |
| Regular emollient use | Helps moisturise dry skin and support skin-barrier care | Ongoing skincare remains important even when eczema symptoms improve |
| Topical corticosteroids | Help control inflammation in affected skin when clinically appropriate | Dupilumab can be used with or without topical corticosteroids according to the individual treatment plan |
| Topical calcineurin inhibitors | Provide a non-steroid topical anti-inflammatory option for selected areas | May be considered for particular problem areas under specialist guidance |
| Trigger and flare management | Helps identify individual factors that may worsen eczema | A personalised plan can help manage periods when symptoms become more active |
| Specialist follow-up | Reviews eczema severity, treatment response, quality of life and adverse effects | Allows the wider treatment plan to be adjusted according to your response and needs |
| Patient education | Supports correct treatment use and realistic expectations | Understanding how each part of the plan works can improve long-term disease management |
Dupilumab does not make everyday skincare and specialist follow-up unnecessary. The most appropriate combination of treatments varies between patients and should be tailored according to disease severity, treatment response, affected areas and individual clinical circumstances.
Personalised Eczema Care
The future of eczema treatment is moving towards a more personalised approach, where your care is tailored to your individual needs rather than using the same treatment for everyone. If you have atopic eczema, this could mean receiving therapies that are better suited to your symptoms, medical history, and the underlying causes of your condition. Personalised medicine aims to improve treatment outcomes while reducing unnecessary trial and error.
Researchers are studying biomarkers and other biological indicators that may help predict how well you are likely to respond to different eczema treatments. By identifying these markers, future biomarker research may help improve treatment selection and identify patient groups more likely to respond to particular therapies helping you achieve better symptom control more quickly. This research is an important step towards more precise and targeted care.
As personalised medicine continues to develop, treatment decisions are expected to become more accurate and individualised. In the future, you may benefit from a care plan that is specifically designed for your condition, giving you a greater chance of long-term eczema control and an improved quality of life.
Global Impact of the LIBERTY AD Studies
The LIBERTY AD programme has had a significant influence on the way moderate-to-severe atopic eczema is treated around the world. If you are receiving care today, many of the treatment recommendations used by dermatologists have been shaped by the evidence generated from these landmark clinical trials. The programme helped establish dupilumab as an important treatment option for people who need more than conventional therapies.
By providing strong evidence from large international studies, the LIBERTY AD programme changed how specialists approach eczema management. It gave doctors greater confidence in prescribing targeted biologic therapy and showed that addressing the underlying immune pathways could lead to better long-term outcomes for you. These findings have influenced clinical guidelines in many countries.
The impact of these studies extends far beyond individual patients. They have driven further research, encouraged the development of new targeted therapies, and improved the standard of care for people living with atopic eczema worldwide. As a result, you now have access to more effective, evidence-based treatment options than ever before.
The Future of Biologic Treatments
Biologic therapies continue to transform the way atopic eczema and other inflammatory skin conditions are treated. If you have moderate-to-severe eczema, ongoing research means that even more targeted treatment options may become available in the coming years. These advances are helping doctors move beyond traditional therapies towards more precise and effective care.
Researchers are now exploring additional immune pathways that may provide new ways to control inflammation and reduce eczema symptoms. By developing medicines that target different parts of your immune system, scientists hope to offer treatments that are better suited to your individual needs and treatment response. This could give you more options if your current therapy is not fully effective.
The progress that began with dupilumab continues to shape the future of dermatology. As new biologic treatments become available, you may benefit from more personalised care, improved long-term symptom control, and a better overall quality of life.
Seeking Specialist Dermatology Advice
If you are living with persistent eczema that is affecting your comfort, sleep, or quality of life, seeking advice from a dermatologist is an important first step. A specialist can assess the severity of your eczema, identify possible triggers, and recommend the treatment options that are most appropriate for your individual needs. Early assessment may also help prevent symptoms from becoming more difficult to manage.
Advances in eczema treatment, including biologic therapies such as dupilumab, have transformed the way moderate-to-severe atopic eczema is managed. However, the most suitable treatment for you will depend on your symptoms, medical history, previous treatments, and overall health. Your dermatologist can explain the benefits and potential risks of each option to help you make an informed decision.
By working closely with a specialist, you can develop a personalised treatment plan that supports long-term eczema control. With the right combination of medical treatment, skincare, and regular follow-up, you can improve your symptoms, reduce flare-ups, and achieve a better quality of life.
Myth vs Fact
| Myth | Fact |
| LIBERTY AD was one single trial. | LIBERTY AD was a broader programme that included several trials involving different populations, treatment combinations and durations. |
| Dupilumab cures eczema permanently. | Dupilumab can provide long-term control for many patients, but atopic eczema remains a chronic condition. |
| Dupilumab directly blocks all immune activity involved in eczema. | It targets IL-4 receptor alpha and inhibits signalling by IL-4 and IL-13, two important type 2 inflammatory pathways. |
| Everyone treated with dupilumab achieves completely clear skin. | Response rates are substantially better than placebo in pivotal trials, but individual responses vary. |
| Dupilumab replaces moisturisers and all topical treatments. | Good skin care remains important, and some patients continue topical anti-inflammatory treatment when clinically appropriate. |
| Long-term studies prove identical results for every patient over five years. | Long-term extension studies support sustained benefit, but open-label designs and smaller patient numbers at later time points must be considered. |
| Biomarker testing can already identify exactly who will respond to dupilumab. | Predictive biomarkers are an active research area but are not yet routinely used to select treatment for every patient. |
| Dupilumab is automatically the first treatment for every person with moderate eczema in the UK. | Eligibility depends on age, disease severity, previous treatment and the relevant UK clinical and commissioning pathway. |
Key Takeaways
- LIBERTY AD was a clinical trial programme rather than one single study.
- SOLO 1 and SOLO 2 involved a combined 1,379 adults and provided major evidence for dupilumab monotherapy.
- In the every-two-week dupilumab groups, approximately 36% to 38% achieved clear or almost clear skin at week 16, compared with 8% to 10% receiving placebo.
- EASI-75 response rates in the same groups were 51% versus 15% in SOLO 1 and 44% versus 12% in SOLO 2.
- CHRONOS showed that dupilumab added to topical corticosteroids provided benefits that could be maintained during one year of treatment.
- CAFE provided important evidence for adults who had inadequate response or intolerance to ciclosporin or for whom ciclosporin was medically inadvisable.
- Dupilumab inhibits IL-4 and IL-13 signalling through the shared IL-4 receptor alpha pathway.
- Long-term open-label evidence supports sustained effectiveness and acceptable safety for many adults continuing treatment, although extension-study limitations need to be acknowledged.
- Current UK licensing covers different age and disease-severity groups, while NICE TA534 provides specific adult eligibility and response criteria.
- Injection-site reactions and eye-related symptoms, particularly conjunctivitis, are important recognised adverse effects to discuss with your dermatologist.
- Dupilumab is an important part of modern eczema treatment, but skin care, follow-up and individual treatment planning remain essential.
FAQs:
1. What were the LIBERTY AD trials?
The LIBERTY AD trials were a series of large Phase III clinical studies that evaluated the effectiveness and safety of dupilumab for people with moderate-to-severe atopic dermatitis. These studies provided important evidence showing that targeted biologic therapy could significantly improve eczema symptoms and quality of life.
2. Why were the LIBERTY AD studies important?
The trials were important because they changed the way doctors understand and treat eczema. They showed that targeting specific immune pathways involved in inflammation could provide better long-term control compared with treatments that mainly focused on symptom relief.
3. What is dupilumab used for?
Dupilumab is a biologic treatment used to manage moderate-to-severe atopic dermatitis. It is designed for patients whose eczema is not adequately controlled with topical treatments or other standard therapies.
4. How does dupilumab work for eczema?
Dupilumab works by blocking the activity of two immune proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13). These pathways play a key role in driving the inflammation associated with atopic dermatitis, and reducing their activity helps calm eczema symptoms.
5. How effective was dupilumab in the LIBERTY AD studies?
The LIBERTY AD trials showed that many patients treated with dupilumab experienced significant improvements in eczema severity, itching, and overall quality of life compared with those receiving placebo treatment.
6. Can dupilumab cure eczema permanently?
No, dupilumab does not cure eczema. However, it can provide long-term control of symptoms by reducing the immune activity responsible for inflammation. Many patients experience sustained improvement while continuing treatment.
7. Does dupilumab help with eczema itching?
Yes, reducing itch was one of the important findings from the LIBERTY AD programme. Many patients reported significant improvements in itching, which can positively affect sleep, comfort, and daily activities.
8. How is dupilumab different from traditional eczema treatments?
Traditional treatments such as topical steroids mainly reduce inflammation after symptoms develop. Dupilumab is different because it targets specific immune pathways involved in causing eczema, offering a more targeted approach to disease management.
9. Is dupilumab safe for long-term use?
The LIBERTY AD trials and follow-up studies have shown that dupilumab has a generally favourable safety profile when used under specialist supervision. Some patients may experience side effects, such as injection-site reactions or eye-related symptoms, which should be discussed with a healthcare professional.
10. Who may benefit from dupilumab treatment?
Dupilumab may be suitable for people with moderate-to-severe atopic dermatitis who have not achieved sufficient control with standard treatments. A dermatologist can assess whether biologic therapy is appropriate based on symptoms, medical history, and treatment response.
Final Thoughts: How the LIBERTY AD Trials Changed the Future of Eczema Treatment
The LIBERTY AD trial programme marked a significant milestone in dermatology by showing how targeted biologic therapies could transform the management of moderate-to-severe atopic eczema. By focusing on the immune pathways responsible for inflammation, dupilumab provided many patients with improved symptom control, reduced itching, and a better quality of life.
Although eczema remains a chronic condition that requires ongoing management, advances in biologic treatments have created new possibilities for people who previously struggled to control their symptoms. The success of dupilumab has also encouraged further research into personalised therapies that target specific causes of inflammatory skin disease. If you would like to book a consultation with one of our Dermatologist in London, you can contact us at the London Dermatology Centre.
References:
- Ortoncelli, M., Macagno, N., Mastorino, L., Gelato, F., Richiardi, I., Cavaliere, G., Quaglino, P. and Ribero, S. (2023) ‘Long-term efficacy and safety of dupilumab in patients with atopic dermatitis: a single-centre retrospective study’, Cosmetics, 10(6), p. 153. Available at: https://www.mdpi.com/2079-9284/10/6/153
- Beck, L.A., Bissonnette, R., Deleuran, M., Nakahara, T., Galus, R., Coleman, A., Gherardi, G., Xiao, J., Dingman, R., Xu, C., Avetisova, E., Dubost-Brama, A. and Shabbir, A. (2024) ‘Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study’, JAMA Dermatology, 160(8), pp. 805–812. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11238067/
- Cather, J., Young, M., DiRuggiero, D.C., Tofte, S., Williams, L. and Gonzalez, T. (2022) ‘A review of phase 3 trials of dupilumab for the treatment of atopic dermatitis in adults, adolescents, and children aged 6 and up’, Dermatology and Therapy, 12(9), pp. 2013–2038. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9464283/
- Simpson et al. (2016) ‘Two phase 3 trials of dupilumab versus placebo in atopic dermatitis’, New England Journal of Medicine, 375(24), pp. 2335–2348. Available at: https://pubmed.ncbi.nlm.nih.gov/27690741/
- Blauvelt et al. (2017) ‘Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial’, The Lancet, 389(10086), pp. 2287–2303. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0140673617311911